You are here:

Bee venom therapy

Apitherapy (bee venom therapy) is the medicinal use of bees or bee products.  There is no research to show it is an effective treatment for people with MS

Therapy with bee venom involves receiving up to 40 stings in a session. Ice is used to numb the skin and to reduce pain. There may be more than one session per week.  The theory behind the treatment is that bee stings cause inflammation.  This leads to an anti-inflammatory response by the immune system. It is suggested that this benefits people with a range of conditions including MS.

There has been very little medical research to support bee venom therapy. In 2005 a small clinical trial compared people having the therapy every week with a group that had no treatment. Results were measured using MRI scans, relapse rate, disability, fatigue and quality of life scales. After 24 weeks, no difference was found between the two groups on any of these measures.

Another small study looked at the use of honeybee venom with people with progressive MS. Although this study found the therapy was safe, the small number of people involved meant it was not possible to draw conclusions about whether it was effective.

In 2008, a review of non-conventional approaches to treating MS found that there was only marginal evidence for bee venom therapy.

Some people can have a severe, potentially fatal, allergic reaction to bee stings.  Anyone undergoing this therapy should have appropriate antihistamine (anti-allergy) drugs immediately to hand.

Last updated: November 2017
Last reviewed: January 2016
This page will be reviewed within three years

More references

  • Namaka M, et al. Examining the evidence: complementary adjunctive therapies for multiple sclerosis. Neurological Research 2008;30(7):710-719. Summary
  • Wesselius T, et al. A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology 2005;6(11):1764-1768. Summary
  • Castro HJ, et al. A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis. Allergy and Asthma Proceedings 2005;26(6):470-476. Summary

Print this page

Rate this page:

Fieldset
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.
*Any personal information will not be followed up or be given to third parties.

Please fill in the fields below if you would like to stay in touch with the MS Trust to help with further testing and feedback on the MS Trust website

Do you have a question about MS? Contact our enquiry team